

Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

CD133/2 (293C3)-PE, human

RRID:AB_244346

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-090-853, RRID:AB_244346

Antibody Information

URL: http://antibodyregistry.org/AB_244346

Proper Citation: Miltenyi Biotec Cat# 130-090-853, RRID:AB_244346

Target Antigen: CD133/2 (293C3)

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 2021; Target Distribution brain, endothelial cells, epithelial cells, heart, hematopoietic stem cells, kidney, liver, lung, pancreas, placenta, ES and iPS cells, red blood cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-186. (RRID:AB_2726012).

Antibody Name: CD133/2 (293C3)-PE, human

Description: This monoclonal targets CD133/2 (293C3)

Target Organism: human

Clone ID: 293C3

Antibody ID: AB_244346

Vendor: Miltenyi Biotec

Catalog Number: 130-090-853

Record Creation Time: 20250820T064928+0000

Record Last Update: 20250821T010008+0000

Ratings and Alerts

No rating or validation information has been found for CD133/2 (293C3)-PE, human.

Warning: Discontinued: 2021

Discontinued: 2021; Target Distribution brain, endothelial cells, epithelial cells, heart, hematopoietic stem cells, kidney, liver, lung, pancreas, placenta, ES and iPS cells, red blood cells; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-186. (RRID:AB_2726012).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang L, et al. (2026) Predictive prioritization of enhancers associated with pancreatic disease risk. Cell genomics, 6(1), 101040.

Verhagen MP, et al. (2024) The SW480 cell line as a model of resident and migrating colon cancer stem cells. iScience, 27(9), 110658.

Sobrino S, et al. (2023) Severe hematopoietic stem cell inflammation compromises chronic granulomatous disease gene therapy. Cell reports. Medicine, 4(2), 100919.

Tatar C, et al. (2023) Doxorubicin-induced senescence promotes resistance to cell death by modulating genes associated with apoptotic and necrotic pathways in prostate cancer DU145 CD133+/CD44+ cells. Biochemical and biophysical research communications, 680, 194.

Zhu P, et al. (2022) 5-hydroxytryptamine produced by enteric serotonergic neurons initiates colorectal cancer stem cell self-renewal and tumorigenesis. Neuron, 110(14), 2268.

Schiroli G, et al. (2019) Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response. Cell stem cell, 24(4), 551.

Petrillo C, et al. (2018) Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. Cell stem cell, 23(6), 820.

Zaikos TD, et al. (2018) Hematopoietic Stem and Progenitor Cells Are a Distinct HIV Reservoir that Contributes to Persistent Viremia in Suppressed Patients. Cell reports, 25(13), 3759.